A new NF‐κB inhibitor attenuates a T H 1 type immune response in a murine model | Zendy

Kabashima Kenji | Zendy; Honda Tetsuya | Zendy; Nunokawa Youichi | Zendy; Miyachi Yoshiki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

A new NF‐κB inhibitor attenuates a T H 1 type immune response in a murine model

Author(s) -

Kabashima Kenji,

Honda Tetsuya,

Nunokawa Youichi,

Miyachi Yoshiki

Publication year - 2004

Publication title -

febs letters

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.593

H-Index - 257

eISSN - 1873-3468

pISSN - 0014-5793

DOI - 10.1016/j.febslet.2004.10.065

Subject(s) - ovalbumin , immune system , nf κb , nfkb1 , in vivo , in vitro , context (archaeology) , chemistry , ex vivo , immunology , biology , pharmacology , microbiology and biotechnology , cancer research , inflammation , biochemistry , transcription factor , paleontology , gene

Nuclear factor kappa B (NF‐κB) plays a wide variety of pathophysiological roles and modulation of its pathway can be a good novel drug target. Here, we found that our recently synthesized NF‐κB inhibitor attenuated an ovalbumin‐specific delayed‐type hypersensitivity response in vivo and suppressed production of IL‐12 by dendritic cells and T H 1 cytokines by T cells in vitro. These findings suggest that the activation of NF‐κB mounts T H 1 type immune responses, and that this new NF‐κB inhibitor has a therapeutic potential in this context.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research